CAR T-cell immunotherapy prompts durable response for ALL – Healio
|
CAR T-cell immunotherapy prompts durable response for ALL
Healio CHICAGO — Young patients with extramedullary relapse of acute lymphoblastic leukemia achieved potent and durable responses to single-agent chimeric antigen receptor T-cell immunotherapy, according to data presented at the ASCO Annual Meeting. |
